By Iain Gilbert
Date: Wednesday 24 Apr 2024
(Sharecast News) - Drugmaker GSK said on Wednesday that the US Food and Drug Administration has accepted a supplemental Biologics License Application for Jemperli, its drug aimed at treating endometrial cancer.
US FDA accepts new indication filing for Jemperli | 24-Apr-2024 | 07:00 | RNS |
Director/PDMR Shareholding | 19-Apr-2024 | 15:30 | RNS |
Director/PDMR Shareholding | 17-Apr-2024 | 15:30 | RNS |
GSK announces additional EAGLE-1 results | 17-Apr-2024 | 07:05 | RNS |
Results from long-term data relating to Shingrix | 17-Apr-2024 | 07:00 | RNS |
GlaxoSmithKline scraps sale of old drugs | 05-Dec-2014 | Telegraph |
Glaxo sharpens axe to save £1bn as insurers and ... | 01-Dec-2014 | The Independent |
GSK to cut hundreds of US jobs | 01-Dec-2014 | Telegraph |
Ebola vaccine trials 'encouraging', says GSK | 27-Nov-2014 | Telegraph |
GlaxoSmithKline tops table in effort to get drug... | 17-Nov-2014 | Guardian |
Questor :GlaxoSmithKline | 16-Apr-2014 | Telegraph |
Questor:GlaxoSmithKline | 06-Oct-2011 | Telegraph |
Questor:GlaxoSmithKline | 11-Aug-2011 | Telegraph |
Questor tip: GlaxoSmithKline | 28-Jul-2011 | Telegraph |
Investment Column: GlaxoSmithKline | 27-Jul-2011 | The Independent |
Currency | UK Pounds |
Share Price | 1,640.50p |
Change Today | 4.50p |
% Change | 0.28 % |
52 Week High | 1,711.20 |
52 Week Low | 1,316.00 |
Volume | 5,015,380 |
Shares Issued | 4,144.88m |
Market Cap | £67,997m |
RiskGrade | 129 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 8 |
Buy | 5 |
Neutral | 9 |
Sell | 2 |
Strong Sell | 0 |
Total | 24 |
Latest | Previous | |
---|---|---|
Q4 | Q3 | |
Ex-Div | 22-Feb-24 | 16-Nov-23 |
Paid | 11-Apr-24 | 11-Jan-24 |
Amount | 16.00p | 14.00p |
Time | Volume / Share Price |
16:35 | 1,722,703 @ 1,640.50p |
16:35 | 157 @ 1,640.50p |
16:35 | 395 @ 1,640.50p |
16:35 | 474 @ 1,640.50p |
16:35 | 2,215 @ 1,640.50p |
You are here: research